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Introduction: Thromboelastography (TEG), a widely used clinical point of care coagulation test, is poorly under-
stood. To investigate its ﬁbrin determinants we used normal and variant ﬁbrinogen isolates.
Materials and Methods:We focused mainly on the TEG maximum signal amplitude (MA), a shear modulus and
clot stiffness indicator. Isolates included normal des-αC, cord, and abnormal congenital variants with amino
acid substitutions or deletions that impaired ﬁbrin polymerization. Heterophenotypic congenital isolates were
from cryoprecipitate-depleted plasma owing to theirmore diminished clotMA than their cryoprecipitate counter-
parts. By colorimetric assay, the amount of ﬁbrinogen adsorbed by untreated TEG cups was 83.5 ± 12.4 pM/cm2,
n = 18. Thrombin-induced clots were obtained at pH 6.4 or 7.4, the latter containing 8 mM CaCl2, and 14%
aﬁbrinogenemic plasma with and without gel-sieved platelets.
Results and Conclusions:Measured by thewaterdroplet contact angle, N90% reduction of surface hydrophobicity by
exposure of TEG cup and pin to ozone plasma decreased MA by 74%. Increasing normal ﬁbrinogen or thrombin
concentrations progressively increased MA. Platelets increased MA further ~2 fold, except for ≥10 fold for des-
αC clots. Examined in the absence of platelets, MA of heterophenotypic ﬁbrin variants averaged 21%, n = 15.
The results imply that essential MA determinants include hydrophobic ﬁbrinogen/ﬁbrin adsorption and each
polymerization contact site, with substantial enhancement by platelets. Also, cryoprecipitate-harvested soluble
ﬁbrinogen/ﬁbrin complexes contained mostly normal molecules, while cryoprecipitate-depleted plasma
contained mostly variant molecules. Moreover, signiﬁcantly decreased MA by ﬁbrinogen anomalies and/or low
level thrombin generation can potentially impact clinical interpretation of MA.© 2014 Elsevier Ltd. All rights reserved.Introduction
Thromboelastography, ﬁrst described by Hartert in 1948 [1], is fre-
quently used in clinical and research settings for assessment of whole
blood or plasma coagulation status. For example, the number of publica-
tions in PubMed during 2010-2013 that mentioned TEG use averaged
136/year. Common TEG uses include assessment and decision makingumamplitude; HPLC, high per-
pB,ﬁbrinopeptide B; SDS-PAGE,
esis; SD, standard deviation.
ital L5, Stony Brook, NY 11790.
e.edu (D.K. Galanakis).for ﬁbrinolytic and anticoagulant therapy and for transfusion after
acute blood loss [2]. The procedure involves an oscillating cup in
which a suspended immobile pin transmits the oscillation effect electro-
mechanically to produce a tuning fork-like signal. The TEG signal is
ﬁbrin dependent, its amplitude is enhanced by platelets, and uniquely
reﬂects the stretch and recovery (shear modulus) of the clot during its
formation. More speciﬁc ﬁbrin determinants remain unknown and
formed the subject of the present study. The ﬁnal step of blood clot
formation involves insoluble ﬁbrin network formed by conversion of
ﬁbrinogen to ﬁbrin [3]. Fibrinogen is a 340 kDa hexameric glycoprotein
composed of 2 sets of 3 different chains Aα, Bβ, γ linked by disulphide
bonds. Following limited proteolysis by thrombin, the resulting ﬁbrin
monomers self-assemble and are covalently cross-linked to strengthen
the clot. Thrombin cleaves 2 pairs of ﬁbrinopeptides, FpA and FpB,
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tively. This exposes pairs of "A" and "B" binding sites or knobs [4] in the
central (or E) part of the molecule. These knobs interact with constitu-
tive sites a and b, known as holes or pockets located in the D regions
of each ﬁbrinogen molecule. Knob A consists of two portions, one
located at the amino terminal region of the Aα chain composing the
amino-terminal α17-20 sequence GPRV [5,6], and the other within
Bβ15-42 [7]. Pocket a encompasses γ337-379 of the D region γmodule
[8,9]. Knob B is also located inβ15-42, and pocket b inβ397-432 of theD
region β module [10,11]. During ﬁbrin self-assembly, a two molecule
thick ﬁbril (protoﬁbril) forms by binding of two molecules to a third
via D:E contacts mediated by knob:pocket interactions. The resulting
D:E:D contact set forms a staggered alignment of monomers that con-
tinues by D:E:D repeats enabling elongation of the protoﬁbril. Another
part of this is the D:D interaction which additionally promotes elonga-
tion, and is mediated by the D interface that resides between γ275R
and γ300S [9]. Following sufﬁcient elongation soluble ﬁbrils associate
laterally and branch leading to ﬁbers and three-dimensional polymers
that coalesce to form the insoluble clot. The αC region originates as
the Aα chain emerges from the D region at Aα220 and terminates at
Aα610 [12]. This region enhances lateral polymerization. In ﬁbrinogen
two αCs interact with each other and with the central (E) region
while in ﬁbrin they switch to intermolecular interactions to form αC-
linked polymers [13]. The elastic capacity of the clot resides in its ﬁbers,
which can stretch to 2.8x before sustaining permanent lengthening and
3.3x before breaking [14]. The clot’s mechanical unraveling reﬂects the
combined effects of unfolding of the two (C-terminal) γ modules, the
reversible extension-contraction of the coiled coil connector [15], and
the αC region [16]. This property, known as clot stiffness, and the
clot’s constitutive capacity to adhere to extravascular surfaces are
among its pivotal hemostasis functions. Studies of naturally occurring
ﬁbrinogen variants corroborated other data that identiﬁed functional
sites [17]. Impaired function of variant structures near or far from such
sites (vide supra) intimated direct or allosteric effects [18].
Our investigations focused on three thromboelastography areas.
One was the cup and pin (hydrophobic) surface, prompted by evidence
that ﬁbrinogen binds rapidly and tightly to hydrophobic and hydrophil-
ic surfaces [19]. The second area was thrombin and ﬁbrinogen dose re-
sponse, in view of evidence the concentration of either can signiﬁcantly
inﬂuence the network structure and stiffness. For example, relatively
low thrombin concentrations induce predominantly coarse and rela-
tively high concentrations predominantly ﬁne and more stiff networks
[20]. The third focus area comprised the ﬁbrin networks of available
ﬁbrinogen variants. The results demonstrate pronounced diminution of
MA by each variant clot, by low thrombin and by low ﬁbrinogen concen-
trations, and by N90% reduction in cup and pin surface hydrophobicity.Materials and Methods
General
Reagents and supplies were purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise speciﬁed. Water was de-ionized (DI)
by ELIX 10 equippedwith continuous UV irradiator (Millipore, Danvers,
MA). Buffers used were either 10 mM Tris-HCL,pH 7.4, 150 mM NaCl
(TBS), or 10 mM PO4, pH 6.4, 150 mM NaCl (PBS). Human factor XIII
was a gift from Dr. R. Chung. Aﬁbrinogenemic and normal human plas-
mawere obtained by plasmapheresis, stored at -80°, and thawed at 37°
prior to use. The aﬁbrinogenemic proband had a life-long hemorrhagic
diathesis with ﬁbrinogen undetectable by functional and by
immunoassay (i.e. b10 mg/dl). Plasma from the other probands was
from blood collected into standard citrate anticoagulant. Monoclonal
IgG antibodies (mAbs) against Aα241-476, Aα518-584 were produced
and stored as described [21]. Recombinant ﬁbrinogen fragments,
Aα221-391 (αC-connector) and Aα392-610 (αC-domain), wereprepared, measured, and stored as described[22]. Plasma-free platelets
were obtained by Sepharose 2B chromatography [23].
TEG
The thromboelastograph 5000was employed according tomanufac-
turer procedure (Haemonetics Corp., Braintree, MA). Its disposable cup
and pin weremanufactured from acrylic polymer (i.e. hydrophobic sur-
face). The pin is a ﬁxed probe linked to a torsion wire and suspended in
the cup that oscillates 4.5° every 5 s. By adhering to both, the forming
clot links cup and pin generating a tuning fork-like time course graph.
The MA (maximum signal amplitude) reﬂects the capacity of forming
clot to recover from the stretching and disruptions (shear modulus)
caused by the oscillating cup, and it is regarded as ameasure of clot stiff-
ness. MA is ﬁbrinogen concentration dependent [24], is increased ~2x
by factor XIIIa-catalyzed ﬁbrin crosslinking [25], and is also increased
~2x by platelets [24], the latter increase mediated by ﬁbrin(ogen) bind-
ing to αIIbβ3 platelet integrin [26].
The cup andpinwere exposed to ozoneplasma to decrease their sur-
face hydrophobicity, illustrated in Fig. 1panel I, a decrease that results
from altered surface end groups [27]. The decrease was demonstrated
by measuring the contact angle of a 5 μl water droplet at room temper-
ature using the CAM200 Optical Contact Angle meter (KSV instruments
LTD., Helsinki, Finland). For this purpose, the cup wall was cut and the
interior surface of the cup bottom was used. The water droplet images
were recorded and stored at a rate of 1 frame per 10 s, and 7 or more
droplets were tested for each experiment. Values of contact angle
were acquired by analyzing the images with the CAM200 software.
For some experiments clots were obtained in PBS, but for most they
were obtained in TBS containing 8 mM CaCl2 with or without 14%
aﬁbrinogenemic plasma. Fibrinogen and thrombin concentrations
were varied as speciﬁed in the Results. For adsorption experiments,
360 μl of 0.5 μM ﬁbrinogen in TBS containing 0.5 mM ethylenediamine-
tetraacetate was incubated in the cup and pin for 3 hours. After remov-
ing the solution andwashingwith excess buffer x3, adsorbed ﬁbrinogen
was measured by the color developed by adding the bicinchoninic acid
reagent (Protein Assay kit, Pierce, Rockford, ILL) according to manufac-
turer instructions. Among normal and abnormal ﬁbrinogen variants the
amounts adsorbed were 83.5 ± 12.4(SD) pM/cm2.
Fibrinogen Isolation
Immunoafﬁnity chromatography was employed using themonoclo-
nal IF1 anti-ﬁbrinogen IgG (Kamiya Biomedical Company, Seattle, WA).
This was covalently linked to CNBr activated Sepharose (Sigma-Aldrich,
St. Louis, MO) according to the latter manufacturer instructions. The
gravity-packed 7 × 0.5 cm column displayed a maximum ﬁbrinogen
binding of 6.3mg. After equilibrationwith 2mMCaCl2 in TBS, an aliquot
of 3ml citrated plasmawasmixedwith an equal volume of TBS contain-
ing 20 mM CaCl2, to neutralize citrate, and applied. Unbound proteins
were removed by gravity ﬂow with ≥5 column volumes of buffer.
Fibrinogen was eluted with 2 mM EDTA in TBS, and concentrated by
precipitation with 25% saturated (NH)2SO4. The precipitate was dis-
solved in 0.3 M NaCl containing 20 nM phenylmethylsulfonylﬂuoride
to neutralize possible protease contaminants, and after 30 or more
minutes it was dialyzed in 0.3 M NaCl, and stored at -70°. Fibrinogen
concentration was measured [28] using the extinction coefﬁcient
(280 nm, 1 cm, 1%) of 15.5. Purity and intactness of its subunit chains
were ascertained after dialysis by electrophoresis in dodecyl sulfate
polyacrylamide (SDS-PAGE) gels [32]. Some heterophenotypic proband
plasmas formedminor precipitates on dilution with the TBS/CaCl2 buff-
er, and these tended tomarkedly slow column ﬂow. This was attributed
to precipitation of soluble ﬁbrin/ﬁbrinogen complexes, was prevented
by using cryoprecipitate-depleted plasma, and led to comparisons of ﬁ-
brinogen isolated [30] from plasma cryoprecipitate [31] and from its
plasma supernatant of 15 different probands. Maximum clot opacities
I II
Control
5 Minutes
10 minutes
MA
Fig. 1. Thrombin and ﬁbrinogen concentration dependence. Panel I: Thromboelastograms showing the effect of three different thrombin concentrations (0.8, 0.1, and 0.005 U/ml),
ﬁbrinogen 4 μM. Panel II: MA plotted as a function of increasing thrombin concentrations. Panel III: Thromboelastograms of four different ﬁbrin(ogen) concentrations (μM) indicated
on each graph, thrombin 0.8 U/ml. Panel IV. A separate set of single experiments showing MA as a function of increasing ﬁbrinogen concentration in the presence (open circles) and
the absence (open squares) of platelets. All experiments were performed in TBS.
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mal controls also obtained from cryoprecipitate. In contrast, clot opaci-
ties of isolates from cryoprecipitate-depleted plasma averaged 33%
(±24%) of corresponding controls. These results led to routine use of
cryoprecipitate-depleted plasma for ﬁbrinogen isolation. To obtain
crosslinked clots, 14% aﬁbrinogenemic plasma was used routinely. To
ascertain that such clots were crosslinked, pilot comparisons of such
clots and those containing factor XIII (50 nM) revealed similarMA. Sep-
arate 30 minute single clots of each variant and controls prepared under
crosslinking conditions were insoluble in 6 M urea. Alternatively, plate-
lets (190 × 103/μl) served as sources of Factor XIII.
Identiﬁcation of Fibrinogen Variants
Coagulable ﬁbrinogen lacking intact Aα chains, old term fraction I-9
and now termed des-αC ﬁbrinogen, displayed intact Bβ and γ chains,
and by gel scanning lacked N95% of intact Aα chains as expected [32].
The αC region [22] consists of a ﬂexible segment known as αC connec-
tor (Aα221-391) and an independently folded segment known as αCTable 1
Characteristics of Fibrinogen Variants.
Name, Dysfunction Variant structure I
Normal Normal -
Des-αC Lacks both αC domains -
Fetal Increased sialylation -
Frankfurt XIII, no FPA release AαR16C, FPA, homodimeric H
Leogan, partial FPA release AαR16C, FPA, Heterodimeric H
Kingsport, slow FPA release AαR16H, Homodimeric P
Louisville, slow FPA release AαR16H, Heterodimeric H
Frankfurt XI, Slow FPA release AαR16S, FPA, Heterodimeric D
Stony Brook III, slow FPA release AαG17V, within knob A, Heterodimeric D
Stony Brook VIII BβR44C, Heterodimeric P
Miami Bβ A61K, Thrombin binding, Heterodimeric P
Omaha Bβ167-171del, coiled coil, Heterodimeric D
Adelphi BβY375C, pocket b, Heterodimeric D
Babylon γY212H, D region, Heterodimeric D
Crete γR275H, D:D, Heterodimeric D
Frankfurt VII γM310T, γN308 glycosyl’n, Het. P
Athens III γD320A, Ca binding, Heterodimeric D
Danville γW335C, Pocket a, Heteodimeric D
Stony Brook VII γA341P, Pocket a, Heterodimeric D
Frankfurt I γA356T, Pocket a, Heterodimeric D
MA:maximum amplitude shown as % of normal control of clots, obtained in TBS containing 14%
dicted by PCR ampliﬁcation andDNA sequencing of corresponding exon. Peptide: protein seque
been previously reported. References following N indicate reported, unrelated probands. HPLCdomain (Aα 392-610) [22]. Des-αC isolates lack N100 C-terminal resi-
dues encompassing most, if not all, [33] of theαC-domain. As indicated
for each in Table 1, congenital ﬁbrinogen variants were identiﬁed by
PCR ampliﬁcation and DNA sequencing [30,34], both DNA and protein
sequencing [34], or protein sequencing only [23,35]. By SDS-PAGE,
unreduced heterophentypic isolates of ﬁbrinogens containing a novel
cysteine displayed no bands larger thanﬁbrinogenmonomers (Adelphi,
Danville, Frankfurt XIII, Leogan, and Stony Brook VIII).Results
Although TEG studies of whole plasma and/or blood have described
the roles of ﬁbrinogen and platelets [24], there is lack of information on
potentially useful speciﬁc ﬁbrin structures that enable or affect the
generation of the TEG signal. To address this question we examined
three aspects of the TEG process. These included the surface adsorption
of ﬁbrinogen/ﬁbrin, effects of different concentration of thrombin and
of isolated normal ﬁbrinogen with and without gel-sieved platelets,dentiﬁcation MA (%) Clinical Association Ref.
100 - -
1.5 Normal catabolite [32]
25 Normal variant [46]
PLC, DNA No clot Hemorrahge, miscarriages [62]
PLC, DNA 35 Asymptomatic [34]
eptide & DNA 100 Hemorrhage. & Thrombosis [30]
PLC 2 Asymptomatic [63]
NA 16 Asymptomatic [64]
NA 6 Asymptomatic N [51]
eptide, DNA 2 Asymptomatic N [65]
eptide, DNA 38 Miscarriages [66]
NA 31 Thrombosis. N [67]
NA 34 Asymptomatic N
NA 16 Hemorrhage, delayed healing N
NA 17 Asymptomatic. [68]
eptide, carbohydrate 32 Hemorrhage. N [56]
NA 38 Asymptomatic N
NA 25 Thrombosis N
NA 22 Intra-partal hemorrhage N
NA 2 Hemorrhage [70]
aﬁbrinogenemic plasma (seeMaterials andMethods). DNA: peptide defect shown is pre-
ncing of appropriate peptide fragment (seeMaterials andMethods). N: the variant has not
: high performance liquid chromatography. Ref.: references. Glycosyl’n: glycosylation.
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abnormal ﬁbrin(ogen) variants.
Initial experiments focused on the effects of varying the thrombin
concentrations. Progressively increasing thrombin concentrations
(ﬁbrinogen 7 μM) shortened the lag time, Fig. 2 panel I, roughly equiv-
alent to gelation or clotting times, and increased MA (panels I and II).
Conversely, decreasing thrombin concentrations yielded lower MA
and longer lag times, as shown. These results are consistent with
other evidence [36] that increasing thrombin concentrations induce
densely ﬁne, highly branched, andmore stiff networks, and low throm-
bin concentrations induce coarse and less stiff networks. The next set of
experiments examined ﬁbrinogen concentrations, illustrated in Fig. 2,
panels III and IV. As shown, increasing ﬁbrinogen concentrations
yielded a corresponding increase inMA. In experiments not shown, fur-
ther increases from 8 μM to15 μM ﬁbrinogen yielded relatively minor
MA increments. The smaller extent of these increments is attributable
to their progressively close proximity to the upper limits of the MA
signal. These results are in general agreement with those reported in
plasma studies [24].
In a related series of experiments we examined the hypothesis that
hydrophobic adsorption plays an important role in long known link
between ﬁbrin and the cup and pin surfaces. Fibrinogen adsorbs to hy-
drophobic and hydrophilic surfaces rapidly (i.e. N90% saturation within
1-2 minutes) [21], a period roughlywithin the TEG lag time. Also,ﬁbrin-
ogen adsorbed to hydrophobic surfaces is uniquely oblong or “stretched
out” and participates in ﬁbrinogen and in ﬁbrin polymerization. To eval-
uate the effect of the hydrophobic cup and pin surface, cup and pinwere
exposed to ozone plasma and thewater droplet contact angle wasmea-
sured. The exposure (see Materials and Methods) decreased the angle
by 84% (from 73° to 12°) at 5 minutes, and by N90% at 10 minutes,
Fig. 1 panel I. As shown, MA of clots formed in the treated cup and pin
was decreased by 50% and by 74 %, respectively. The latter also resulted
in a shallower TEG slope. These result established that hydrophobic ad-
sorption is a major MA determinant.
The foregoing results raised the question whether some or all inter-
molecular ﬁbrin polymerization contacts are also required for generation
of theMA signal. To address this, clots fromcongenitalﬁbrinogen variants
with known aberrant structures were used. The results providedI I
III I
0.8
0.1
0.005
6
3
1
0.3
MA
Fig. 2. Ionizing radiation-treated cup and pin. I: Decreasedwater contact angle shown in º (ordin
RT: right angle. II: Thromboelastograms, obtained in PBS following cup and pin exposure to ozevidence from one variant that aberrant structures that delayed FpA re-
lease, delaying polymerization, also delayed MA development, Fig. 3
panel I. Also, variants that impaired intermolecular contacts diminished
MA, illustrated in Fig. 3 panel II. To conduct these experiments, advantage
was taken of isolates from cryoprecipitate-depleted plasma (see Mate-
rials and Methods) whose MA decrease was more pronounced than
that of their cryoprecipitate counterparts (Fig. 3, panel III). Clots were ex-
amined in the presence of aﬁbrinogenemic plasma with or without gel-
sieved platelets. The known enhancement of MA by platelets [24] is at-
tributable to their clot retraction capacity and to their factor XIII release,
activated to XIIIa by thrombin in the clot and, resulting in ﬁbrin
crosslinking. Factor XIIIa-catalyzes formation of covalent reciprocal brid-
ges between γ398/399Q of one and γ406K of a juxtaposed ﬁbrin mono-
mer forming ﬁbrin dimers. Such crosslinks are also formed, albeit more
slowly, among multiple monomers, involving corresponding residues at
four interior α chain sites. Additionally, some bridges form between γ
and α chains. The resulting γ chain-crosslinked clot becomes more rigid
and resistant to deformation, and displays elasticity up to a maximum
stretch of 1.8 fold [37] accounting for its increased stiffness [38]. Although
crosslinking and platelet integrin (αIIbβ3, γ400- 411) binding sites over-
lap [39,40], both function independently [37]. In addition, hydrophobic
surface adsorption exposes γ112-119 and Aα95-98 (RGD) both of
which interact with platelets [41]. To maximize MA relatively high
thrombin concentrations (e.g. 1 U/ml) were used. Clots from 7 μM ﬁbrin-
ogen obtained in the absence of platelets, Table 1, yielded the two general
patterns shown. One was prolonged lag time and normal MA by a
homophenotypic variant, Fig. 3 panel I. The other was prolonged lag
time and decreased MA, panel II, displayed by the heterophenotypic var-
iants.MAof heterophenotypic variant clots ranged from1% to 38% of con-
trols. Platelets increased normal ﬁbrin MA ~2 fold, not shown, in general
agreement with another report [24], and also increased the MA of
heterophenotypic variant clots from a mean (% of controls, Table 1) of
21 ± 13.5 to 37 ± 20.7. In summary, the foregoing results established
that all congenital variants that impaired intermolecular contacts dimin-
ished clot stiffness.
A catabolic structural variant, des-αC ﬁbrinogen, was also inves-
tigated. This variant represent a minor normal circulating ﬁbrinogen
fraction [32] which is coagulable, displays prolonged clotting times,0.0 0.1 0.2 0.3 0.4 0.5 0.6
0
20
40
60
Thrombin U/ml
M
A
 (m
m)
I
V
ate) as a function of time (abscissa) by cup and pin exposure to ozoneplasma. LT: left angle,
one plasma for 5 and 10 minutes, decreasing MA to 46% and 36% of control, respectively.
CAαR16H (Kingsport)
C
BβR44C (Stony Brook VII)
Cryo
-Cryo
γR275H (Crete)
I II
III IV
C
Fig. 3. Thromboelastograms of congenital ﬁbrinogen variants. I: Fibrinogen Kingsport (4 μM. 0.5 thrombin) clot showing prolonged lag time and normal MA. C: normal ﬁbrin control. II:
Fibrinogen Crete clot, showing prolonged lag time and markedly diminished MA. III: Comparison of ﬁbrinogen isolates from cryoprecipitate (Cryo) and cryoprecipitate-depleted (-Cryo)
plasma of ﬁbrinogen Stony Brook VII, showing a more marked MA decrease by –Cryo. IV: MA comparison of clots from heterophenotypic congenital Cryo and -Cryo ﬁbrinogen isolates,
n = 15. Clots of I, II, and III were obtained in TBS, pH 7.4, 8 mM CaCl2, 14% aﬁbrinogenemic plasma. In addition those of III contained platelets (seeMaterials andMethods). IV: Histograms
showing the markedly decreased MA of single clots from 15 heterophenotypic ﬁbrinogen variants. Clotting conditions were as in III.
1119D.K. Galanakis et al. / Thrombosis Research 133 (2014) 1115–1123ﬁne ﬁbrin networks [42], and decreased clot stiffness [38]. In intact
ﬁbrinogen, theαC region is a knownmajor determinant of clot stiffness
[43], and is critical to the adsorption induced (non-enzymatic) ﬁbrino-
gen self-assembly [21]. Numerous des-αC ﬁbrinogen clots consistently
yielded little or negligible MA, illustrated in Fig. 4, panel I. To exclude a
possible adsorption effect, des-αC clots were formed in cup and pinI   C
III
Aα
Bβ
γ
Des-αC Intact  
Des-αC
Fig. 4. Thromboelastograms showing the critical role ofﬁbrinαC region, clotting conditions as in
intact ﬁbrin control (C). II: MA of three des-αC clots obtained in the absence, left, and presence
trace amounts of intact Aα chains as compared to those of ﬁbrinogenwith intact Aα chains, righ
mAbs (8 μM, see Materials and Methods) markedly decreased its MA. MAb 1: anti-Aα241-476containing adsorbed intact ﬁbrinogen, and they also showed little or no
MA signal, n = 3, not shown. These results established that the absence
of intermolecular αC-αC interactions accounted for the nearly absent
MA. They also indicated that the αC domain is a critical determinant of
MA, since in des-αC isolatesN95%ofmolecules lack this domain [44]. Per-
haps not surprisingly, their MA was partly corrected by platelets, aII
IV
C
1
Mabs 2
Fig. 3, panel III. I: thromboelastogram of des-αC ﬁbrin showing diminishedMA, relative to
, right, of platelets. III: Electrophoretogram of two des-αC isolates, left lanes, showing only
t lane. Panel IV: Thromboelastograms of intact normal ﬁbrin showing that each of the two
. Mab 2: anti-Aα518-584.
1120 D.K. Galanakis et al. / Thrombosis Research 133 (2014) 1115–1123correction that ranged from 31%-74% of clots from intact ﬁbrin controls,
Fig. 4, panel II. This correction is consistent with the predominant role
in binding to platelets by the C-terninal γ dodecapeptide [45]. In a single
other experiment, not shown, this increase could not be diminished by
the presence either Mab (vide infra), suggesting it was not attributable
to the minor or trace amounts of intact Aα chains shown in Fig. 4, panel
III.
In related experiments the possible effects of two mAbs directed at
each of the two parts of αC (see Materials and Methods) were exam-
ined. Each mAb was previously shown [21] to moderately decrease
clot turbidity but not impair coagulability. Each mAb (0.5 μM) was
incubated overnight in the cup and pin containing previously adsorbed
intact ﬁbrinogen, and after washing, a solution containing intact ﬁbrin-
ogen was introduced and clotted. In two separate duplicate experi-
ments, one shown in Fig. 4, panel IV, each mAb all but abolished MA.
In additional control experiments not shown, each Mab was incubated
with untreated cup and pin and showed no effect on the MA of intact
ﬁbrin.
In another set of related experiments, the possible effect on MA by
each of three recombinant Aα fragments, Aα241-471(αC connector),
Aα472-610 (αC domain), and Aα241-610 (αC) was explored. In pilot
experiments, cup and pin were incubated overnight with 0.5 μM
fragment and washed prior to introduction of the clotting mixture.
This resulted in no effect onMAby any of the three fragments. However,
when cup and pin contained adsorbed intact ﬁbrinogen, and then
incubated with each fragment and washed, the MA of intact ﬁbrin was
moderately increased (Fig. 5, panels I and II). Moreover, clot turbidity
maxima (350 nm), expressed as % of fragment-free controls, were
78%, 81%, and 84% by fragments αC-connector, αC-domain, and αC,
respectively, Fig. 5, panel III. Taken together, the foregoing results
established that both αC parts of intact ﬁbrin, the αC domain and the
αC connector, independently enhanced MA. (See Fig. 6.)
Examination of a second normal variant, cord or fetal ﬁbrinogen
disclosedmarkedly decreasedMA, Table 1. Paradoxically, its clot opacityαC domain
αC connector 
αC 
Control
I
Fig. 5. Enhanced clotMA by recombinantαC fragments. I: thromboelastograms of normal ﬁbrin
II: MeanMA and range, n = 3, of separate experiments performed under the same conditions a
Each fragment was added to a solution of normal ﬁbrinogen (1.4 μM), fragment: ﬁbrinogen rais typically decreased [46] indicating ﬁner andmore branched network.
Such network in normal adult ﬁbrinogen displays increased stiffness
(i.e. MA) relative to its coarse counterpart [36]. By contrast, MA of
fetal ﬁbrin clots was decreased, a characteristic attributable to its
increased sialic acid content [46,47].
Discussion
Themost important result was the greatly diminishedMA, reﬂecting
clot stiffness, by all variants with impaired ﬁbrin polymerization.
Considering the vigorous tear-and-recovery (shear modulus) of the
forming clot, the diminished MA in each case reﬂected its impaired
polymerization capacity. Unexpectedly, the impaired polymerization
also accounted for the relative separation of normal from variant mole-
cules during cryoprecipitation. That is to say, considering that in the
plasma ﬁbrinogen population ~50% are heterodimers and 25% variant
homodimers [48] the Cryo and –Cryo data (vide supra) implied that
these two abnormal populations participated minimally in soluble
ﬁbrinogen/ﬁbrin complexes. As a result the circulating complexes
contained mostly normal homodimers. This is attributable to their
relatively greater afﬁnity for complex formation and thus selectively
enriched the plasma cryoprecipitate. As a consequence cryoprecipitate-
depleted plasma was relatively more enriched with variant monomers.
By extension, the dysfunction of each variant was more pronounced
owing to depletion of normal monomers. An unresolved question was
that most dysﬁbrinogens were heterophenotypic and the speciﬁc roles
in the diminished MA by abnormal homodimers and by heterodimers
could not be separated. Nevertheless, the unmistakable MA diminution
can only be attributed to effects of by abnormal structure in each case,
whether or not the two molecular species acted similarly or each by a
distinct mechanism.
The diminished MA of our variant isolates revealed previously
unknown determinants of MA which arguably encompass all known
polymerization contacts. Moreover, the alteration of the mechanismsIII   
II
(1.4 μM, pH 6.4) formed in cup and pin previously exposed to each fragment, andwashed.
s in I. III: Single experiments showing a modest decrease of clot opacity by each fragment.
tio 3:1, and allowed to stand for 10 minutes prior to adding thrombin.
γA356T, 4%  
γA341P, 19%
γW335C, 45%  
γR275H, 13%
γR275C,  4%
AαR16H, 100%
AαR16C, 31%
AαG17V, 2%
AαR19G  7%
BβR44C, 6%,                                                                  
BβA61K, 16%
γY212H,15%
γD320A,38%
Bβ167-171del,5%
γM310T, 3%
Absence , <2% 
BβY375C, 34%
Fig. 6. Fibrinogen molecule cartoon, adapted from [59], indicating the approximate location of each variant structure and its MA shown as % of normal control, also speciﬁed in Table 1.
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determinants of clot stiffness. In one variant group, impaired polymeri-
zation of (heterodimeric and homodimeric) AαR16C ﬁbrin reﬂects is its
uncleaved variant FpA and thereby non-engagement of its knob A.
Although mutant Aα16C homodimers per se are incoagulable at 37°
(the temperature of the TEGprocedure), it is highly likely they participate
in heterodimer polymerization. This is suggested by their capacity to
form ﬁbrils at ambient and subambient temperatures [49] and implies a
signiﬁcant level of B:b contacts during protoﬁbril elongation. A somewhat
similar possible explanationmay account for themarkedMA decrease in
heterophenotypic AαR16S and AαR16H clots. Release of FpA from either
variant structure is signiﬁcantly slower than that of its FpB [30], resulting
in delayed exposure of the second knob A. That is to say, the normally
concerted ﬁrst and second FpA release enables rapid availability of both
knobs (A and A) leading to initiation and progression of protoﬁbril
assembly mainly if not exclusively via A:a interactions [50]. The clearly
delayed release of the variant (or second) FpA, therefore, limits its A:a
contact rate. This likely favors more frequent B:b contacts during ﬁbril
elongation than their A:a counterparts. These possible explanations are
consistent with i) their markedly decreased clot opacity implying
decreased lateral contacts, ii) ﬁne ﬁber clots formed by AαR16C
homodimers per se at ambient and sub-ambient temperatures [49] and
in mixtures with heterodimers [23] at 37°. Normal clot stiffness when
all FpA is released from homodimeric AαR16H [30] suggests that even
at FpA release rates that are slower than those of FpB, the slowly exposed
knobs still form A:a and/or possibly A:b contacts.
In a second variant group, diminished MA by defects in knob A and
pocket a underscore the pivotal role by A:a contacts. Apparently, substi-
tution of a Val for Gly17 impairs both thrombin-catalyzed FpA release
and polymerization since the peptide Val-Pro-Arg-Val partially inhibits
ﬁbrin polymerization [51]. Also, decreased MA by Aα R19G impairs
the ability of knob A to interact with pocket a. Structural data indicate
that the free amino group of the knob A mimic (GPRPam) interacts
directly with the side chain of residue γD364 in pocket a, suggesting
that the side chain is not critical [52]. Structure data also show that
the positively charged side chain of R19 interacts with residues in pock-
et a, such as γD330. Consequently, substitution with glycine (G) will
abolish these interactions. In summary, substitutions within knob A
(AαG17V and AαR19H), or pocket a (γW335C, γA341P, γA356T) alldiminished MA implying that the normally tight A:a contacts [53] are
necessary for clot stiffness.
In a third variant group, the pronounced decrease inMA by pocket b
variant (BβY375C) clots is surprising. That is, the B:b bonds are six times
weaker than those of A:a [54] and their easy disruption by the TEG oscil-
lation is expected. However, themagnitude of theirMAdiminution sug-
gests a signiﬁcant role in clot stiffness. A similar discrepancy emerges
from the decreased MA by the γR275H and γR275C variants. The
γR375 and γS300 segment contains the D:D interface, an intermolecu-
lar contact generally regarded asweaker than that of A:a. InD:D contact,
the R275 of one molecule normally contacts γY280 of another with a
reciprocal asymmetric link from γS300 extending back across the D:D
interface to γR275 of the ﬁrst molecule [9]. The γR275 (H or C) substi-
tutions lack the R side group and are expected to result in a weaker or
unstable D:D abutment. Again, the marked MA diminution suggests
that D:D contact is required for clot stiffness. A possible explanation
for the decreased MA by the γM310T substitution with extra glycosyla-
tion at γN308 is that it reﬂects a perturbation within pocket a, since
removal of the novel carbohydrate cluster does not correct the dysfunc-
tion [56]. Lastly, the γD320A substitution is near both the Calcium
binding site and the pocket a, and may impair both functions.
In a fourth variant group, decreased MA by the Bβ44 and Bβ61 sub-
stitutions is attributable to their proximity to the second part of knob A
(β15-42, vide supra) exerting an inhibiting effect on A:a contacts.
Impaired B:b contacts per se are also possible since the defects are
near knob B, notwithstanding possible disruption of A:b contacts [54].
The decreased clot MA by the Bβ 167-171 del is within the coiled coil,
possibly reﬂects stiffening of this region which normally accounts for
most of the elasticity of the molecule [57], and may indirectly impair
A:a or other contacts. Alternatively, it may impair intermolecular coiled
coil contacts demonstrable in the ﬁbrinogen crystal and likely to occur
in polymerized ﬁbrin [58]. Either possibility is consistent with impaired
polymerization by other coiled coil mutations [59].
A normal variant, des-αC ﬁbrinogen, yielded clots with negligible
MA, a behavior consistent with the enhanced polymerization by the
αC region [60] and its major role in clot stiffness [38]. Moreover, the
diminished MA is clearly attributable to the absence of the αC domain,
a structural characteristic of des-αC ﬁbrinogen (vide supra), and there-
fore implies that the αC domain is a major MA determinant. Marked,
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and likely reﬂects platelet αIIbβ3 binding to the γ chain C-terminal
dodecapeptide which remains exposed in crosslinked clots [61]. More-
over it suggests that is also necessary for maximum clot stiffness. Plate-
lets ostensibly serve to complement and re-enforce themajor role ofαC.
This suggestion is consistent with blocking of the binding by an anti-
αIIbβ3 mAb, resulting in marked diminution of MA [26]. Moreover, the
magnitude of correction, unmasks a much greater clot stiffness role by
platelet retraction than is demonstrable with intact ﬁbrin clots. What
is more, the incomplete platelet correction implies that each Aα chain
part, the αC domain and the αC connector, is a determinant of maxi-
mum clot stiffness. Another normal variant, fetal ﬁbrinogen possesses
increased phosphorus and sialic acid content [47]. It is unclear how
either or both of these two end groups account for the diminished clot
opacity [46] and stiffness (present data). Similarly decreased opacity
by congenital variants with extra carbohydrate clusters and the correc-
tive effect by desialylation in some and deglycosylation in others [17,
59], suggest allosteric and/or electrostatic hindrance effects. In summa-
ry, the data underscore that ﬁbrin polymerization is so ﬁne-tuned that
perturbation of any intermolecular contact and even minor differences
in sialylation that alter network structure diminish clot stiffness.
The ﬁbrinogen dose response suggests that asymptomatic
hypoﬁbrinogenemia (i.e. with mildly abnormal or normal coagulation
test results)maymore readily diminishMA andbe interpreted as unduly
excessive blood loss in surgical/trauma settings. Similarly, dose response
by thrombin suggests that minimal activation conditions such as
recalciﬁcation may generate relatively low thrombin levels yielding
low blood MA. This could be misinterpreted as decreased ﬁbrinogen
level and impact clinical decisions.
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